ONCO Share Price Performance
CA$1.98
1.33 (204.62%)
Price CA$1.98
Share PriceCA$1.98
ONCO Community Narratives
There are no narratives available yet.
Recent ONCO News & Updates
No updates
Onco-Innovations Limited Key Details
Last Reported Earnings
Apr 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.16
- Gross Margin
- 100.00%
- Net Profit Margin
- -13,010.36%
- Debt/Equity Ratio
- 0%
Onco-Innovations Limited Competitors
About ONCO
- Founded
- n/a
- Employees
- 1
- CEO
- WebsiteView website
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. The company’s lead product candidate is ONC010, a novel inhibitor of the DNA repair enzyme a Polynucleotide Kinase 3'-Phosphatase (PNKP) in a nanoparticle formulation based on the drug delivery technology. Onco-Innovations Limited is headquartered in Calgary, Canada.
Canadian Market Performance
- 7 Days: -1.4%
- 3 Months: 8.0%
- 1 Year: 18.6%
- Year to Date: 8.7%
Over the last 7 days, the market has dropped 1.7%, driven by a decline of 2.5% in the Financials sector. In contrast to the last week, the market is actually up 19% over the past year. Looking forward, earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading